How to Navigate Ecosystem Connect NEWDistinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats
A Seamless Phase 1/2 Open-label Study to Evaluate the Safety, Determine the Maximum Tolerated Dose of Administered Activity, and Evaluate the Efficacy of the Therapeutic Radiopharmaceutical [Ac 225]-RTX-2358 in the Treatment of Relapsed or Refractory Sarcoma
Description:
The goal of this clinical trial is to learn about the safety of drug [Ac225]RTX-2358 and the diagnostic imaging agent [Cu64]LNTH-1363S. Additionally Ratio Therapeutics will learn if [Ac225]RTX-2358 drug is effective in treating advanced sarcoma.
Sponsor:
Ratio Therapeutics, IncContacts:
TBDtbd@tbd.com
Government Study Link:
NCT07156565 - Click here to see study onClinicalTrials.gov
[Cu64]LNTH-1363S
Isotope(s):
Target(s):
- FAP
Ligand: Small Molecules
Chelator: NOTA
[Ac225]RTX-2358
Isotope(s):
Target(s):
- FAP
Ligand: Small Molecules
Chelator: Macropa™
Linker: Trillium™
Patient Education
Patient Education Not Yet Provided
Publications
Publications Not Yet Provided
Locations
United States 🇺🇸
TBD
United States
